Navellier & Associates’s Taro Pharmaceutical Industries Ltd. TARO Stock Holding History

Navellier & Associates’s Portfolio TARO Stock Details TARO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-4,335	Closed	-$611K	–	397
2015 Q1	$611K	Sell	4,335 -1,028	-19%	-$158K	0.06%	164
2014 Q4	$795K	Sell	5,363 -1,477	-22%	-$217K	0.04%	130
2014 Q3	$1.05M	Buy	6,840 +1,341	+24%	+$202K	0.05%	100
2014 Q2	$771K	Sell	5,499 -4,673	-46%	-$519K	0.03%	129
2014 Q1	$1.13M	Sell	10,172 -7,761	-43%	-$845K	0.05%	87
2013 Q4	$1.77M	Sell	17,933 -262	-1%	-$22.7K	0.08%	70
2013 Q3	$1.38M	Buy	18,195 +14	+0.1%	+$908	0.04%	100
2013 Q2	$1.02M	Buy	+18,181	New	+$1.07M	0.05%	109

Other funds holding TARO

ICM

ISZO Capital Management New York $2M AUM 35.61% 1-Year Est. Return

MICM

Matthews International Capital Management San Francisco, California $292M AUM 75.01% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

GCM

Greywolf Capital Management Purchase, New York $67.3M AUM 100.05% 1-Year Est. Return

RCM

Raging Capital Management Rocky Hill, New Jersey $18.2M AUM 17.75% 1-Year Est. Return

Think Investments San Francisco, California $847M AUM 88.1% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $34.3B AUM 22.63% 1-Year Est. Return

AIM

Assured Investment Management New York $79.5M AUM 115.55% 1-Year Est. Return

MCP

Moab Capital Partners Southampton, New York $41M AUM 33.21% 1-Year Est. Return

Navellier & Associates's TARO Position: Q2 2015 in Review

Navellier & Associates sold out of Taro Pharmaceutical Industries Ltd. (TARO) in Q2 2015, closing a stake of 4,335 shares — an estimated $611K sold.

Navellier & Associates first reported a position in TARO in Q2 2013 and held it in 8 quarters. The position peaked at $1.77M in Q4 2013. 106 funds tracked by Wall St. Rank hold TARO as of Q2 2015.

Navellier & Associates reported no remaining Taro Pharmaceutical Industries Ltd. position as of Q2 2015 after selling out during the quarter.
Navellier & Associates sold 4,335 Taro Pharmaceutical Industries Ltd. shares in Q2 2015, an estimated $611K.
Navellier & Associates first reported a position in Taro Pharmaceutical Industries Ltd. in Q2 2013 and held it in 8 quarters.
Navellier & Associates's Taro Pharmaceutical Industries Ltd. position peaked at $1.77M in Q4 2013.
106 funds tracked by Wall St. Rank held Taro Pharmaceutical Industries Ltd. as of Q2 2015.

Based on Navellier & Associates's 13F filing for Q2 2015, filed 8 Jul 2015.